EPS Surged to 1.27 HK Cents with a Three-year CAGR of 43.1%Robust Revenue Growth Driven by Strong Demand for Bogutai® and Omnichannel Strategy
2025-08-29
View details
On June 27, 2025, Uni-Bio Science Group Limited grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌颜态® and the medical device brand 金因敷®.
2025-07-02
View details
金因康® (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字 H20254149].
2025-05-22
View details
Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M，First-ever Dividend was HK$0.277 Cents Per Share，Strengthening Presence in Osteoporosis，Ophthalmology, and Aesthetic Medical Markets
2025-03-27
View details
2nd December 2024 –Uni-Bio Science Group Limited is pleased to announce two significant milestones that demonstrate the Group’s continued growth and innovation in the field of medical aesthetics and dermatological solutions.
2024-12-02
View details
京公网安备 11011402013046号京ICP备17029593号-2
